This case was reported in a literature article and described the occurrence of suspected vaccination failure in a subject who received Meningococcal B Recom vaccine + AlOH + OMV for prophylaxis. In February 2016, unknown after receiving Meningococcal B Recom vaccine + AlOH + OMV and Meningococcal B Recom vaccine + AlOH + OMV, the subject developed vaccination failure. Serious criteria included GSK medically significant. Additional event(s) included meningococcal infection in February 2016 with serious criteria of GSK medically significant. The outcome of vaccination failure was unknown. The outcome(s) of the additional event(s) included meningococcal infection (unknown). The investigator considered that there was a reasonable possibility that the vaccination failure and meningococcal infection may have been caused by Meningococcal B Recom vaccine + AlOH + OMV and Meningococcal B Recom vaccine + AlOH + OMV. Additional information was provided. This case was reported in a literature article and described the suspected vaccination failure in a patient of unspecified age and gender who was vaccinated with unspecified meningococcal B (MenB) vaccine (manufacturer unknown) for prophylaxis. The patient corresponds to table 1 in this literature article. The patient was a part of the study that summarized the university-based outbreaks of meningococcal disease caused by serogroup B in the years following MenB vaccine availability (2013-2018) and described the resulting MenB vaccination responses. The patient was an undergraduate student. The patient belonged to university outbreak during January to February 2016. No information on patient's family or medical history or concurrent condition or concomitant medication was provided. On unspecified dates, the patient received 2 doses of unspecified MenB vaccine (administration route and site unspecified; batch number not provided). Age of vaccination was not provided. On an unspecified date in February 2016, an unknown period after vaccination, the patient developed meningococcal B disease. It was reported that the patient had received antimicrobial chemoprophylaxis the day before symptom onset and it was a suspected case with inconclusive lab results. This case has been considered as suspected vaccination failure being time to onset was unknown. This case has been considered serious due to suspected vaccination failure. Treatment was unknown. The outcome of the event was not reported. The author did not comment on the relationship between the event of rotavirus infection and unspecified rotavirus vaccine. The author stated, "This is the first full genome characterization of DS-1-like G1P[8] strains that have emerged in specific countries. Its detection may imply the ongoing spread of these unusual RVA strains outside of specific area. PCR-based genotyping allied with PAGE analysis could be easily applied to detect atypical DS-1-like G1P[8] strains, although whole genome-based analysis are still essential. Global RVA strain collection is imperative in order to determine the exact origin(s) of the DS-1-like G1P[8] strains. In addition, an intensive, distinct surveillance system, focused on determining if the available RVA vaccines are still effective against unusual DS-1-like G1P[8] strains, as well as investigating whether these recently emerged G1P[8] double-gene reassortant strains cause more-severe disease must be developed." This is 1 of the 2 valid cases reported in the same literature article.